CN106102775A - 治疗纤维变性疾病的方法 - Google Patents
治疗纤维变性疾病的方法 Download PDFInfo
- Publication number
- CN106102775A CN106102775A CN201580007480.7A CN201580007480A CN106102775A CN 106102775 A CN106102775 A CN 106102775A CN 201580007480 A CN201580007480 A CN 201580007480A CN 106102775 A CN106102775 A CN 106102775A
- Authority
- CN
- China
- Prior art keywords
- combination
- modulator
- fibrosis
- gene
- modulators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003176 fibrotic effect Effects 0.000 title claims abstract description 180
- 238000000034 method Methods 0.000 title claims abstract description 143
- 238000011282 treatment Methods 0.000 title claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 302
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 190
- 208000035475 disorder Diseases 0.000 claims abstract description 97
- 201000010099 disease Diseases 0.000 claims abstract description 93
- 238000013519 translation Methods 0.000 claims description 241
- 210000000651 myofibroblast Anatomy 0.000 claims description 80
- 108010085279 eukaryotic translation initiation factor 5A Proteins 0.000 claims description 64
- 206010016654 Fibrosis Diseases 0.000 claims description 61
- 101100232687 Drosophila melanogaster eIF4A gene Proteins 0.000 claims description 60
- 230000004761 fibrosis Effects 0.000 claims description 59
- 102000004169 proteins and genes Human genes 0.000 claims description 57
- -1 PAQR5PLEKHG1 Proteins 0.000 claims description 48
- 102100039487 Deoxyhypusine hydroxylase Human genes 0.000 claims description 46
- 108010028753 deoxyhypusine hydroxylase Proteins 0.000 claims description 46
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 claims description 41
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 claims description 41
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 36
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 34
- GVKXFVCXBFGBCD-QKDMMWSPSA-N silvestrol Chemical compound CO[C@@H]1OC[C@H]([C@H](O)CO)O[C@H]1OC(C=C1OC)=CC2=C1[C@]1(O)[C@H](O)[C@H](C(=O)OC)[C@@H](C=3C=CC=CC=3)[C@]1(C=1C=CC(OC)=CC=1)O2 GVKXFVCXBFGBCD-QKDMMWSPSA-N 0.000 claims description 33
- 229940124597 therapeutic agent Drugs 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 239000000523 sample Substances 0.000 claims description 32
- GVKXFVCXBFGBCD-UHFFFAOYSA-N silvestrol Natural products COC1OCC(C(O)CO)OC1OC(C=C1OC)=CC2=C1C1(O)C(O)C(C(=O)OC)C(C=3C=CC=CC=3)C1(C=1C=CC(OC)=CC=1)O2 GVKXFVCXBFGBCD-UHFFFAOYSA-N 0.000 claims description 31
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 25
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims description 25
- 229960003073 pirfenidone Drugs 0.000 claims description 24
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims description 22
- 230000007246 mechanism Effects 0.000 claims description 22
- 230000008859 change Effects 0.000 claims description 19
- 230000006378 damage Effects 0.000 claims description 18
- 102000005234 Adenosylhomocysteinase Human genes 0.000 claims description 16
- 108020002202 Adenosylhomocysteinase Proteins 0.000 claims description 16
- 102100022913 NAD-dependent protein deacetylase sirtuin-2 Human genes 0.000 claims description 16
- 108010041216 Sirtuin 2 Proteins 0.000 claims description 16
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 15
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 14
- 210000000056 organ Anatomy 0.000 claims description 14
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 14
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 claims description 13
- 101000926530 Homo sapiens Eukaryotic translation initiation factor 2-alpha kinase 1 Proteins 0.000 claims description 13
- 101000926508 Homo sapiens Eukaryotic translation initiation factor 2-alpha kinase 3 Proteins 0.000 claims description 13
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 claims description 13
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 claims description 13
- 102100039980 40S ribosomal protein S18 Human genes 0.000 claims description 12
- 102100033731 40S ribosomal protein S9 Human genes 0.000 claims description 12
- 102100021546 60S ribosomal protein L10 Human genes 0.000 claims description 12
- 102100032682 Dimethylaniline monooxygenase [N-oxide-forming] 2 Human genes 0.000 claims description 12
- 102100022537 Histone deacetylase 6 Human genes 0.000 claims description 12
- 101000811259 Homo sapiens 40S ribosomal protein S18 Proteins 0.000 claims description 12
- 101000657066 Homo sapiens 40S ribosomal protein S9 Proteins 0.000 claims description 12
- 101001108634 Homo sapiens 60S ribosomal protein L10 Proteins 0.000 claims description 12
- 101000974043 Homo sapiens Ribosome biogenesis protein NOP53 Proteins 0.000 claims description 12
- 102100022399 Ribosome biogenesis protein NOP53 Human genes 0.000 claims description 12
- 108010057167 dimethylaniline monooxygenase (N-oxide forming) Proteins 0.000 claims description 12
- 239000000835 fiber Substances 0.000 claims description 12
- 238000010606 normalization Methods 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 101100093804 Caenorhabditis elegans rps-6 gene Proteins 0.000 claims description 9
- 230000033228 biological regulation Effects 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims description 8
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims description 8
- 239000013068 control sample Substances 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 8
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 7
- 102100031334 Elongation factor 2 Human genes 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims description 6
- 102100026744 40S ribosomal protein S10 Human genes 0.000 claims description 6
- 102100031571 40S ribosomal protein S16 Human genes 0.000 claims description 6
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims description 6
- 102100022681 40S ribosomal protein S27 Human genes 0.000 claims description 6
- 102100031928 40S ribosomal protein S29 Human genes 0.000 claims description 6
- 102100023779 40S ribosomal protein S5 Human genes 0.000 claims description 6
- 102100037663 40S ribosomal protein S8 Human genes 0.000 claims description 6
- 102100033416 60S acidic ribosomal protein P1 Human genes 0.000 claims description 6
- 102100026112 60S acidic ribosomal protein P2 Human genes 0.000 claims description 6
- 102100025643 60S ribosomal protein L12 Human genes 0.000 claims description 6
- 102100022289 60S ribosomal protein L13a Human genes 0.000 claims description 6
- 102100031854 60S ribosomal protein L14 Human genes 0.000 claims description 6
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 6
- 102100021690 60S ribosomal protein L18a Human genes 0.000 claims description 6
- 102100037965 60S ribosomal protein L21 Human genes 0.000 claims description 6
- 102100038008 60S ribosomal protein L22-like 1 Human genes 0.000 claims description 6
- 102100021308 60S ribosomal protein L23 Human genes 0.000 claims description 6
- 102100028348 60S ribosomal protein L26 Human genes 0.000 claims description 6
- 102100021927 60S ribosomal protein L27a Human genes 0.000 claims description 6
- 102100021660 60S ribosomal protein L28 Human genes 0.000 claims description 6
- 102100040540 60S ribosomal protein L3 Human genes 0.000 claims description 6
- 102100038237 60S ribosomal protein L30 Human genes 0.000 claims description 6
- 102100023777 60S ribosomal protein L31 Human genes 0.000 claims description 6
- 102100040637 60S ribosomal protein L34 Human genes 0.000 claims description 6
- 102100022276 60S ribosomal protein L35a Human genes 0.000 claims description 6
- 102100022048 60S ribosomal protein L36 Human genes 0.000 claims description 6
- 102100040131 60S ribosomal protein L37 Human genes 0.000 claims description 6
- 102100036126 60S ribosomal protein L37a Human genes 0.000 claims description 6
- 102100026926 60S ribosomal protein L4 Human genes 0.000 claims description 6
- 102100026750 60S ribosomal protein L5 Human genes 0.000 claims description 6
- 102100036630 60S ribosomal protein L7a Human genes 0.000 claims description 6
- 108091005663 ADAMTS5 Proteins 0.000 claims description 6
- 102000051389 ADAMTS5 Human genes 0.000 claims description 6
- 102100026397 ADP/ATP translocase 3 Human genes 0.000 claims description 6
- 102100025261 AMSH-like protease Human genes 0.000 claims description 6
- 102100023587 ATP synthase F(0) complex subunit C2, mitochondrial Human genes 0.000 claims description 6
- 102100036612 ATP-binding cassette sub-family A member 6 Human genes 0.000 claims description 6
- 102100022117 Abnormal spindle-like microcephaly-associated protein Human genes 0.000 claims description 6
- 102100036826 Aldehyde oxidase Human genes 0.000 claims description 6
- 102100031993 Amphoterin-induced protein 3 Human genes 0.000 claims description 6
- 102000004000 Aurora Kinase A Human genes 0.000 claims description 6
- 108090000461 Aurora Kinase A Proteins 0.000 claims description 6
- 102100024747 Band 4.1-like protein 1 Human genes 0.000 claims description 6
- 102100021950 Basic immunoglobulin-like variable motif-containing protein Human genes 0.000 claims description 6
- 101710036791 CEP192 Proteins 0.000 claims description 6
- 102100029391 Cardiotrophin-like cytokine factor 1 Human genes 0.000 claims description 6
- 102100025634 Caspase recruitment domain-containing protein 16 Human genes 0.000 claims description 6
- 102100024911 Caveolae-associated protein 4 Human genes 0.000 claims description 6
- 102100036178 Centrosomal protein of 192 kDa Human genes 0.000 claims description 6
- 102100038941 Coiled-coil domain-containing protein 102B Human genes 0.000 claims description 6
- 102100023677 Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial Human genes 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 102100027309 Cyclic AMP-responsive element-binding protein 5 Human genes 0.000 claims description 6
- 102100037147 Cytoplasmic dynein 2 heavy chain 1 Human genes 0.000 claims description 6
- 102100033587 DNA topoisomerase 2-alpha Human genes 0.000 claims description 6
- 102100022872 Deoxyribonuclease-1-like 1 Human genes 0.000 claims description 6
- 102100022874 Dexamethasone-induced Ras-related protein 1 Human genes 0.000 claims description 6
- 102100022266 DnaJ homolog subfamily C member 22 Human genes 0.000 claims description 6
- 241001669680 Dormitator maculatus Species 0.000 claims description 6
- 101150115146 EEF2 gene Proteins 0.000 claims description 6
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 claims description 6
- 102100033902 Endothelin-1 Human genes 0.000 claims description 6
- 102100029602 Eukaryotic translation initiation factor 4B Human genes 0.000 claims description 6
- 102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 claims description 6
- 102100029327 FERM domain-containing protein 4A Human genes 0.000 claims description 6
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 6
- 102100023941 G-protein-signaling modulator 2 Human genes 0.000 claims description 6
- 102100031158 GAS2-like protein 3 Human genes 0.000 claims description 6
- 108010001498 Galectin 1 Proteins 0.000 claims description 6
- 102100021736 Galectin-1 Human genes 0.000 claims description 6
- 102100028689 Glucocorticoid-induced transcript 1 protein Human genes 0.000 claims description 6
- 102100021223 Glucosidase 2 subunit beta Human genes 0.000 claims description 6
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 claims description 6
- 102100032820 HIG1 domain family member 2A, mitochondrial Human genes 0.000 claims description 6
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims description 6
- 102100023607 Homer protein homolog 1 Human genes 0.000 claims description 6
- 101001119189 Homo sapiens 40S ribosomal protein S10 Proteins 0.000 claims description 6
- 101000706746 Homo sapiens 40S ribosomal protein S16 Proteins 0.000 claims description 6
- 101000733040 Homo sapiens 40S ribosomal protein S19 Proteins 0.000 claims description 6
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 claims description 6
- 101000704060 Homo sapiens 40S ribosomal protein S29 Proteins 0.000 claims description 6
- 101000622644 Homo sapiens 40S ribosomal protein S5 Proteins 0.000 claims description 6
- 101001097439 Homo sapiens 40S ribosomal protein S8 Proteins 0.000 claims description 6
- 101000712357 Homo sapiens 60S acidic ribosomal protein P1 Proteins 0.000 claims description 6
- 101000691878 Homo sapiens 60S acidic ribosomal protein P2 Proteins 0.000 claims description 6
- 101000575173 Homo sapiens 60S ribosomal protein L12 Proteins 0.000 claims description 6
- 101000681240 Homo sapiens 60S ribosomal protein L13a Proteins 0.000 claims description 6
- 101000704267 Homo sapiens 60S ribosomal protein L14 Proteins 0.000 claims description 6
- 101001117935 Homo sapiens 60S ribosomal protein L15 Proteins 0.000 claims description 6
- 101000682512 Homo sapiens 60S ribosomal protein L17 Proteins 0.000 claims description 6
- 101000752293 Homo sapiens 60S ribosomal protein L18a Proteins 0.000 claims description 6
- 101000661708 Homo sapiens 60S ribosomal protein L21 Proteins 0.000 claims description 6
- 101000661567 Homo sapiens 60S ribosomal protein L22-like 1 Proteins 0.000 claims description 6
- 101000675833 Homo sapiens 60S ribosomal protein L23 Proteins 0.000 claims description 6
- 101001080179 Homo sapiens 60S ribosomal protein L26 Proteins 0.000 claims description 6
- 101000753696 Homo sapiens 60S ribosomal protein L27a Proteins 0.000 claims description 6
- 101000676271 Homo sapiens 60S ribosomal protein L28 Proteins 0.000 claims description 6
- 101000673985 Homo sapiens 60S ribosomal protein L3 Proteins 0.000 claims description 6
- 101001101319 Homo sapiens 60S ribosomal protein L30 Proteins 0.000 claims description 6
- 101001113162 Homo sapiens 60S ribosomal protein L31 Proteins 0.000 claims description 6
- 101000672659 Homo sapiens 60S ribosomal protein L34 Proteins 0.000 claims description 6
- 101001110988 Homo sapiens 60S ribosomal protein L35a Proteins 0.000 claims description 6
- 101001110263 Homo sapiens 60S ribosomal protein L36 Proteins 0.000 claims description 6
- 101000671735 Homo sapiens 60S ribosomal protein L37 Proteins 0.000 claims description 6
- 101001092424 Homo sapiens 60S ribosomal protein L37a Proteins 0.000 claims description 6
- 101000691203 Homo sapiens 60S ribosomal protein L4 Proteins 0.000 claims description 6
- 101000691083 Homo sapiens 60S ribosomal protein L5 Proteins 0.000 claims description 6
- 101000853243 Homo sapiens 60S ribosomal protein L7a Proteins 0.000 claims description 6
- 101000648020 Homo sapiens AMSH-like protease Proteins 0.000 claims description 6
- 101000905797 Homo sapiens ATP synthase F(0) complex subunit C2, mitochondrial Proteins 0.000 claims description 6
- 101000929676 Homo sapiens ATP-binding cassette sub-family A member 6 Proteins 0.000 claims description 6
- 101000900939 Homo sapiens Abnormal spindle-like microcephaly-associated protein Proteins 0.000 claims description 6
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 claims description 6
- 101000776186 Homo sapiens Amphoterin-induced protein 3 Proteins 0.000 claims description 6
- 101000970720 Homo sapiens Basic immunoglobulin-like variable motif-containing protein Proteins 0.000 claims description 6
- 101000777555 Homo sapiens CCN family member 3 Proteins 0.000 claims description 6
- 101000800624 Homo sapiens CST complex subunit TEN1 Proteins 0.000 claims description 6
- 101000714497 Homo sapiens Carbonic anhydrase 5B, mitochondrial Proteins 0.000 claims description 6
- 101000989964 Homo sapiens Cardiotrophin-like cytokine factor 1 Proteins 0.000 claims description 6
- 101000933103 Homo sapiens Caspase recruitment domain-containing protein 16 Proteins 0.000 claims description 6
- 101000761524 Homo sapiens Caveolae-associated protein 4 Proteins 0.000 claims description 6
- 101000740823 Homo sapiens Coiled-coil domain-containing protein 102B Proteins 0.000 claims description 6
- 101000907013 Homo sapiens Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial Proteins 0.000 claims description 6
- 101000726193 Homo sapiens Cyclic AMP-responsive element-binding protein 5 Proteins 0.000 claims description 6
- 101000881344 Homo sapiens Cytoplasmic dynein 2 heavy chain 1 Proteins 0.000 claims description 6
- 101000902865 Homo sapiens Deoxyribonuclease-1-like 1 Proteins 0.000 claims description 6
- 101000620808 Homo sapiens Dexamethasone-induced Ras-related protein 1 Proteins 0.000 claims description 6
- 101000902105 Homo sapiens DnaJ homolog subfamily C member 22 Proteins 0.000 claims description 6
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 claims description 6
- 101000925493 Homo sapiens Endothelin-1 Proteins 0.000 claims description 6
- 101000840282 Homo sapiens Eukaryotic translation initiation factor 4B Proteins 0.000 claims description 6
- 101001054354 Homo sapiens Eukaryotic translation initiation factor 5A-1 Proteins 0.000 claims description 6
- 101001062454 Homo sapiens FERM domain-containing protein 4A Proteins 0.000 claims description 6
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 claims description 6
- 101000904754 Homo sapiens G-protein-signaling modulator 2 Proteins 0.000 claims description 6
- 101001066167 Homo sapiens GAS2-like protein 3 Proteins 0.000 claims description 6
- 101001058426 Homo sapiens Glucocorticoid-induced transcript 1 protein Proteins 0.000 claims description 6
- 101001040875 Homo sapiens Glucosidase 2 subunit beta Proteins 0.000 claims description 6
- 101000893563 Homo sapiens Growth/differentiation factor 10 Proteins 0.000 claims description 6
- 101001066452 Homo sapiens HIG1 domain family member 2A, mitochondrial Proteins 0.000 claims description 6
- 101001048469 Homo sapiens Homer protein homolog 1 Proteins 0.000 claims description 6
- 101000977768 Homo sapiens Interleukin-1 receptor-associated kinase 3 Proteins 0.000 claims description 6
- 101001007397 Homo sapiens Leukocyte receptor cluster member 9 Proteins 0.000 claims description 6
- 101000938676 Homo sapiens Liver carboxylesterase 1 Proteins 0.000 claims description 6
- 101001025971 Homo sapiens Lysine-specific demethylase 6B Proteins 0.000 claims description 6
- 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 claims description 6
- 101000605006 Homo sapiens Lysosome-associated membrane glycoprotein 5 Proteins 0.000 claims description 6
- 101000588145 Homo sapiens Microtubule-associated tumor suppressor 1 Proteins 0.000 claims description 6
- 101000648421 Homo sapiens Mitochondrial import receptor subunit TOM7 homolog Proteins 0.000 claims description 6
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 claims description 6
- 101000588247 Homo sapiens Nascent polypeptide-associated complex subunit alpha Proteins 0.000 claims description 6
- 101000981973 Homo sapiens Nascent polypeptide-associated complex subunit alpha, muscle-specific form Proteins 0.000 claims description 6
- 101000585675 Homo sapiens Obscurin Proteins 0.000 claims description 6
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 claims description 6
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 claims description 6
- 101000730665 Homo sapiens Phospholipase D1 Proteins 0.000 claims description 6
- 101001096178 Homo sapiens Pleckstrin homology domain-containing family A member 5 Proteins 0.000 claims description 6
- 101001096179 Homo sapiens Pleckstrin homology domain-containing family A member 6 Proteins 0.000 claims description 6
- 101001067189 Homo sapiens Plexin-A1 Proteins 0.000 claims description 6
- 101000735358 Homo sapiens Poly(rC)-binding protein 2 Proteins 0.000 claims description 6
- 101000609219 Homo sapiens Polyadenylate-binding protein 4 Proteins 0.000 claims description 6
- 101000952078 Homo sapiens Probable ATP-dependent RNA helicase DDX60 Proteins 0.000 claims description 6
- 101000928339 Homo sapiens Progressive ankylosis protein homolog Proteins 0.000 claims description 6
- 101000740825 Homo sapiens Protein C10 Proteins 0.000 claims description 6
- 101000801282 Homo sapiens Protein O-mannosyl-transferase TMTC1 Proteins 0.000 claims description 6
- 101000928406 Homo sapiens Protein diaphanous homolog 3 Proteins 0.000 claims description 6
- 101001099888 Homo sapiens Ras-related protein Rab-3D Proteins 0.000 claims description 6
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 claims description 6
- 101000650697 Homo sapiens Roundabout homolog 2 Proteins 0.000 claims description 6
- 101000654560 Homo sapiens SH3-containing GRB2-like protein 3-interacting protein 1 Proteins 0.000 claims description 6
- 101000652366 Homo sapiens Spermatogenesis-associated protein 6 Proteins 0.000 claims description 6
- 101000596086 Homo sapiens TATA box-binding protein-associated factor RNA polymerase I subunit D Proteins 0.000 claims description 6
- 101000800639 Homo sapiens Teneurin-1 Proteins 0.000 claims description 6
- 101000633608 Homo sapiens Thrombospondin-3 Proteins 0.000 claims description 6
- 101000642512 Homo sapiens Transcription factor SOX-5 Proteins 0.000 claims description 6
- 101000642517 Homo sapiens Transcription factor SOX-6 Proteins 0.000 claims description 6
- 101000634900 Homo sapiens Transcriptional-regulating factor 1 Proteins 0.000 claims description 6
- 101000617779 Homo sapiens U1 small nuclear ribonucleoprotein A Proteins 0.000 claims description 6
- 101000982047 Homo sapiens Unconventional myosin-XIX Proteins 0.000 claims description 6
- 101000818832 Homo sapiens Zinc finger protein 608 Proteins 0.000 claims description 6
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 claims description 6
- 101001117266 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 7B Proteins 0.000 claims description 6
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 6
- 102100027004 Inhibin beta A chain Human genes 0.000 claims description 6
- 102100023530 Interleukin-1 receptor-associated kinase 3 Human genes 0.000 claims description 6
- 208000002260 Keloid Diseases 0.000 claims description 6
- 102100024629 Laminin subunit beta-3 Human genes 0.000 claims description 6
- 102100028296 Leukocyte receptor cluster member 9 Human genes 0.000 claims description 6
- 101000964266 Loxosceles laeta Dermonecrotic toxin Proteins 0.000 claims description 6
- 102100037461 Lysine-specific demethylase 6B Human genes 0.000 claims description 6
- 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 claims description 6
- 102100038212 Lysosome-associated membrane glycoprotein 5 Human genes 0.000 claims description 6
- 108010072582 Matrilin Proteins Proteins 0.000 claims description 6
- 102100031347 Metallothionein-2 Human genes 0.000 claims description 6
- 102100031550 Microtubule-associated tumor suppressor 1 Human genes 0.000 claims description 6
- 102100028764 Mitochondrial import receptor subunit TOM7 homolog Human genes 0.000 claims description 6
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 claims description 6
- 102100026779 Nascent polypeptide-associated complex subunit alpha, muscle-specific form Human genes 0.000 claims description 6
- 102000048238 Neuregulin-1 Human genes 0.000 claims description 6
- 108090000556 Neuregulin-1 Proteins 0.000 claims description 6
- 102100030127 Obscurin Human genes 0.000 claims description 6
- 102100037602 P2X purinoceptor 7 Human genes 0.000 claims description 6
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 6
- 102100037866 Pleckstrin homology domain-containing family A member 5 Human genes 0.000 claims description 6
- 102100037869 Pleckstrin homology domain-containing family A member 6 Human genes 0.000 claims description 6
- 102100034961 Poly(rC)-binding protein 2 Human genes 0.000 claims description 6
- 102100039424 Polyadenylate-binding protein 4 Human genes 0.000 claims description 6
- 102100037439 Probable ATP-dependent RNA helicase DDX60 Human genes 0.000 claims description 6
- 102100036812 Progressive ankylosis protein homolog Human genes 0.000 claims description 6
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 claims description 6
- 102100038957 Protein C10 Human genes 0.000 claims description 6
- 102100033739 Protein O-mannosyl-transferase TMTC1 Human genes 0.000 claims description 6
- 102100036468 Protein diaphanous homolog 3 Human genes 0.000 claims description 6
- 102100024245 Putative inactive carbonic anhydrase 5B-like protein Human genes 0.000 claims description 6
- 102100038474 Ras-related protein Rab-3D Human genes 0.000 claims description 6
- 102100025234 Receptor of activated protein C kinase 1 Human genes 0.000 claims description 6
- 108010044157 Receptors for Activated C Kinase Proteins 0.000 claims description 6
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims description 6
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 6
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 claims description 6
- 102100027739 Roundabout homolog 2 Human genes 0.000 claims description 6
- 102100032641 SH3-containing GRB2-like protein 3-interacting protein 1 Human genes 0.000 claims description 6
- 108091006595 SLC15A3 Proteins 0.000 claims description 6
- 108091006495 SLC25A6 Proteins 0.000 claims description 6
- 108091006310 SLC2A12 Proteins 0.000 claims description 6
- 108091006976 SLC40A1 Proteins 0.000 claims description 6
- 206010039710 Scleroderma Diseases 0.000 claims description 6
- 102100021485 Solute carrier family 15 member 3 Human genes 0.000 claims description 6
- 102100039671 Solute carrier family 2, facilitated glucose transporter member 12 Human genes 0.000 claims description 6
- 102100032008 Solute carrier family 40 member 1 Human genes 0.000 claims description 6
- 102100030258 Spermatogenesis-associated protein 6 Human genes 0.000 claims description 6
- 102100035207 TATA box-binding protein-associated factor RNA polymerase I subunit D Human genes 0.000 claims description 6
- 102100033213 Teneurin-1 Human genes 0.000 claims description 6
- 102100029524 Thrombospondin-3 Human genes 0.000 claims description 6
- 102100036692 Transcription factor SOX-5 Human genes 0.000 claims description 6
- 102100036694 Transcription factor SOX-6 Human genes 0.000 claims description 6
- 102100029446 Transcriptional-regulating factor 1 Human genes 0.000 claims description 6
- 108010040633 Transforming Protein 3 Src Homology 2 Domain-Containing Proteins 0.000 claims description 6
- 102000002013 Transforming Protein 3 Src Homology 2 Domain-Containing Human genes 0.000 claims description 6
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 6
- 102100022013 U1 small nuclear ribonucleoprotein A Human genes 0.000 claims description 6
- 102100026769 Unconventional myosin-XIX Human genes 0.000 claims description 6
- 102100021354 Zinc finger protein 608 Human genes 0.000 claims description 6
- ZPCCSZFPOXBNDL-ZSTSFXQOSA-N [(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2r,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoe Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 ZPCCSZFPOXBNDL-ZSTSFXQOSA-N 0.000 claims description 6
- 230000001746 atrial effect Effects 0.000 claims description 6
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 claims description 6
- 102100024232 cAMP-specific 3',5'-cyclic phosphodiesterase 7B Human genes 0.000 claims description 6
- 230000009787 cardiac fibrosis Effects 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims description 6
- 108010041998 erythrocyte membrane protein band 4.1-like 1 Proteins 0.000 claims description 6
- 108010019691 inhibin beta A subunit Proteins 0.000 claims description 6
- 230000000302 ischemic effect Effects 0.000 claims description 6
- 108010028309 kalinin Proteins 0.000 claims description 6
- 210000001117 keloid Anatomy 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 206010028537 myelofibrosis Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 208000011317 telomere syndrome Diseases 0.000 claims description 6
- MWZMHLBLVDPOJE-UHFFFAOYSA-N 1-[4-[[n'-(4,6-dimethylpyrimidin-2-yl)carbamimidoyl]amino]phenyl]sulfonyl-3-phenylurea Chemical compound CC1=CC(C)=NC(N=C(N)NC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC=2C=CC=CC=2)=N1 MWZMHLBLVDPOJE-UHFFFAOYSA-N 0.000 claims description 5
- 102000019050 90-kDa Ribosomal Protein S6 Kinases Human genes 0.000 claims description 5
- 108010012196 90-kDa Ribosomal Protein S6 Kinases Proteins 0.000 claims description 5
- 102100026656 Actin, alpha skeletal muscle Human genes 0.000 claims description 5
- 102100037278 Actin-related protein 2/3 complex subunit 1A Human genes 0.000 claims description 5
- 102100032385 Ankyrin repeat and death domain-containing protein 1A Human genes 0.000 claims description 5
- 101000834207 Homo sapiens Actin, alpha skeletal muscle Proteins 0.000 claims description 5
- 101000806644 Homo sapiens Actin-related protein 2/3 complex subunit 1A Proteins 0.000 claims description 5
- 101000797936 Homo sapiens Ankyrin repeat and death domain-containing protein 1A Proteins 0.000 claims description 5
- 101000975502 Homo sapiens Keratin, type II cytoskeletal 7 Proteins 0.000 claims description 5
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 claims description 5
- 206010023330 Keloid scar Diseases 0.000 claims description 5
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 claims description 5
- 102100020880 Kit ligand Human genes 0.000 claims description 5
- 239000012678 infectious agent Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 206010073306 Exposure to radiation Diseases 0.000 claims description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 229940125939 BMS-986202 Drugs 0.000 claims description 2
- 108010089484 PRM-151 Proteins 0.000 claims description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
- 229960000830 captopril Drugs 0.000 claims description 2
- 239000002532 enzyme inhibitor Substances 0.000 claims description 2
- ZMDQCRVENVSDDY-JOCZSTLJSA-N euk 207 Chemical compound [Mn].CC(O)=O.O1CCOCCOCCOC(C2=O)=CC=C/C2=C/NCCN/C=C2/C=CC=C1C2=O ZMDQCRVENVSDDY-JOCZSTLJSA-N 0.000 claims description 2
- HPHXKNOXVBFETI-SHCCRYCOSA-N hippuristanol Chemical compound O1C(C)(C)[C@@H](C)C[C@]11[C@@](O)(C)[C@@H]2[C@@]3(C)C[C@H](O)[C@@H]4[C@@]5(C)CC[C@@H](O)C[C@@H]5CC[C@H]4[C@@H]3C[C@@H]2O1 HPHXKNOXVBFETI-SHCCRYCOSA-N 0.000 claims description 2
- HPHXKNOXVBFETI-UHFFFAOYSA-N hippuristanol Natural products O1C(C)(C)C(C)CC11C(O)(C)C2C3(C)CC(O)C4C5(C)CCC(O)CC5CCC4C3CC2O1 HPHXKNOXVBFETI-UHFFFAOYSA-N 0.000 claims description 2
- 229950002183 lebrikizumab Drugs 0.000 claims description 2
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 claims description 2
- DSPNTLCJTJBXTD-IRNRRZNASA-N pateamine Chemical compound C[C@H]1C[C@@H](N)CC(=O)O[C@@H](C)C\C(C)=C\C=C/C(=O)O[C@H](\C=C(/C)\C=C\C(\C)=C\CN(C)C)CC2=NC1=CS2 DSPNTLCJTJBXTD-IRNRRZNASA-N 0.000 claims description 2
- DSPNTLCJTJBXTD-UHFFFAOYSA-N pateamine A Natural products CC1CC(N)CC(=O)OC(C)CC(C)=CC=CC(=O)OC(C=C(C)C=CC(C)=CCN(C)C)CC2=NC1=CS2 DSPNTLCJTJBXTD-UHFFFAOYSA-N 0.000 claims description 2
- 229940121324 romilkimab Drugs 0.000 claims description 2
- 229950009513 simtuzumab Drugs 0.000 claims description 2
- 229950000835 tralokinumab Drugs 0.000 claims description 2
- 102100022462 Eukaryotic initiation factor 4A-II Human genes 0.000 claims 8
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 claims 7
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims 7
- 108010057194 Eukaryotic Initiation Factor-4F Proteins 0.000 claims 5
- 102100023679 40S ribosomal protein S28 Human genes 0.000 claims 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 4
- 102000002322 Egg Proteins Human genes 0.000 claims 4
- 108010000912 Egg Proteins Proteins 0.000 claims 4
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 4
- 101000623076 Homo sapiens 40S ribosomal protein S28 Proteins 0.000 claims 4
- 102100033670 Matrilin-3 Human genes 0.000 claims 4
- 210000000589 cicatrix Anatomy 0.000 claims 4
- 235000014103 egg white Nutrition 0.000 claims 4
- 210000000969 egg white Anatomy 0.000 claims 4
- 239000003337 fertilizer Substances 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 230000001568 sexual effect Effects 0.000 claims 4
- 241000894007 species Species 0.000 claims 4
- 102100031242 Deoxyhypusine synthase Human genes 0.000 claims 3
- 101000844963 Homo sapiens Deoxyhypusine synthase Proteins 0.000 claims 3
- 101000959666 Homo sapiens Eukaryotic initiation factor 4A-I Proteins 0.000 claims 3
- 101001044475 Homo sapiens Eukaryotic initiation factor 4A-II Proteins 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 2
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 102000005233 Eukaryotic Initiation Factor-4E Human genes 0.000 claims 1
- 108060002636 Eukaryotic Initiation Factor-4E Proteins 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 210000000630 fibrocyte Anatomy 0.000 claims 1
- SLRCCWJSBJZJBV-BYNSBNAKSA-N genisteine Chemical compound C1N2CCCC[C@@H]2[C@@H]2CN3CCCC[C@@H]3[C@H]1C2 SLRCCWJSBJZJBV-BYNSBNAKSA-N 0.000 claims 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
- 229960004378 nintedanib Drugs 0.000 claims 1
- 238000010200 validation analysis Methods 0.000 claims 1
- 229940076155 protein modulator Drugs 0.000 abstract 1
- 230000014616 translation Effects 0.000 description 242
- 210000002950 fibroblast Anatomy 0.000 description 98
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 91
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 91
- 210000004027 cell Anatomy 0.000 description 60
- 230000000694 effects Effects 0.000 description 59
- MFAQYJIYDMLAIM-UHFFFAOYSA-N torkinib Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC2=CC(O)=CC=C2N1 MFAQYJIYDMLAIM-UHFFFAOYSA-N 0.000 description 44
- 108020004999 messenger RNA Proteins 0.000 description 42
- 230000037361 pathway Effects 0.000 description 37
- 238000004519 manufacturing process Methods 0.000 description 34
- 230000001105 regulatory effect Effects 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 34
- 150000001875 compounds Chemical class 0.000 description 33
- 108010050808 Procollagen Proteins 0.000 description 28
- 230000004547 gene signature Effects 0.000 description 26
- 101710088791 Elongation factor 2 Proteins 0.000 description 25
- 230000002401 inhibitory effect Effects 0.000 description 23
- 108010085238 Actins Proteins 0.000 description 20
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 20
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 19
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 19
- 229940124647 MEK inhibitor Drugs 0.000 description 19
- 102000038030 PI3Ks Human genes 0.000 description 19
- 108091007960 PI3Ks Proteins 0.000 description 19
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 19
- 108020004459 Small interfering RNA Proteins 0.000 description 17
- 102000007469 Actins Human genes 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 15
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 230000000903 blocking effect Effects 0.000 description 15
- 210000002744 extracellular matrix Anatomy 0.000 description 15
- 230000028327 secretion Effects 0.000 description 15
- 230000009466 transformation Effects 0.000 description 15
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 14
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 14
- 101000611643 Homo sapiens Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 description 14
- 102100040714 Protein phosphatase 1 regulatory subunit 15A Human genes 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 230000008816 organ damage Effects 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 239000012472 biological sample Substances 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 101710091919 Eukaryotic translation initiation factor 4G Proteins 0.000 description 12
- 239000000090 biomarker Substances 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 229940124302 mTOR inhibitor Drugs 0.000 description 12
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 238000001262 western blot Methods 0.000 description 12
- 108010093366 eIF-4B Proteins 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000003705 ribosome Anatomy 0.000 description 10
- 208000019425 cirrhosis of liver Diseases 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 230000037390 scarring Effects 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 102100034169 Eukaryotic translation initiation factor 2-alpha kinase 1 Human genes 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 210000004024 hepatic stellate cell Anatomy 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 108010023925 Histone Deacetylase 6 Proteins 0.000 description 5
- 208000029523 Interstitial Lung disease Diseases 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 229940125632 eukaryotic translation initiation factor 4A inhibitor Drugs 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 4
- 101100542977 Arabidopsis thaliana PIPC gene Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 description 4
- 206010042953 Systemic sclerosis Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000003068 pathway analysis Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 230000007781 signaling event Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 101150097381 Mtor gene Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008236 biological pathway Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- DBZQFUNLCALWDY-PNHWDRBUSA-N (2r,3r,4s,5r)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DBZQFUNLCALWDY-PNHWDRBUSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 2
- 102100033756 39S ribosomal protein L45, mitochondrial Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101100286382 Drosophila melanogaster eIF2beta gene Proteins 0.000 description 2
- 101100396397 Drosophila melanogaster eIF2gamma gene Proteins 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 101150039757 EIF3E gene Proteins 0.000 description 2
- 102100033132 Eukaryotic translation initiation factor 3 subunit E Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101000733888 Homo sapiens 39S ribosomal protein L45, mitochondrial Proteins 0.000 description 2
- 101000989478 Homo sapiens Uncharacterized protein C9orf85 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 2
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 102000055008 Matrilin Proteins Human genes 0.000 description 2
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 2
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010036805 Progressive massive fibrosis Diseases 0.000 description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 2
- 101710188306 Protein Y Proteins 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101100279491 Schizosaccharomyces pombe (strain 972 / ATCC 24843) int6 gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100029322 Uncharacterized protein C9orf85 Human genes 0.000 description 2
- 102100035071 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010820 immunofluorescence microscopy Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- LHHJINYPOFGQEJ-UHFFFAOYSA-N 1-(2,1,3-benzoxadiazol-5-yl)-3-(4-chlorophenyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC2=NON=C2C=C1 LHHJINYPOFGQEJ-UHFFFAOYSA-N 0.000 description 1
- 101150066838 12 gene Proteins 0.000 description 1
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 1
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- BBRMAVGRWHNAIG-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[3-(5-fluoropyrimidin-2-yl)-2-methoxyanilino]-N-(trideuteriomethyl)pyridine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=NC=C(C(=O)NC([2H])([2H])[2H])C(=C1)NC1=C(C(=CC=C1)C1=NC=C(C=N1)F)OC BBRMAVGRWHNAIG-FIBGUPNXSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010066728 Acute interstitial pneumonitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- DTEKTGDVSARYDS-UHFFFAOYSA-N BI-D1870 Chemical compound N1=C2N(CCC(C)C)C(C)C(=O)N(C)C2=CN=C1NC1=CC(F)=C(O)C(F)=C1 DTEKTGDVSARYDS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 108010033333 DEAD-box RNA Helicases Proteins 0.000 description 1
- 102000007120 DEAD-box RNA Helicases Human genes 0.000 description 1
- 102000048231 Deoxyhypusine synthases Human genes 0.000 description 1
- 108700023218 Deoxyhypusine synthases Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101710196289 Eukaryotic translation initiation factor 2-alpha kinase 1 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000003433 Gingival Pocket Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 1
- 102100035621 Heterogeneous nuclear ribonucleoprotein A1 Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000854014 Homo sapiens Heterogeneous nuclear ribonucleoprotein A1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000785 Invasive Pulmonary Aspergillosis Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 201000004073 acute interstitial pneumonia Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940125528 allosteric inhibitor Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003138 coordinated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 108010037623 eIF-2 Kinase Proteins 0.000 description 1
- 102000010982 eIF-2 Kinase Human genes 0.000 description 1
- 230000000463 effect on translation Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- CPMDPSXJELVGJG-UHFFFAOYSA-N methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate Chemical compound OC=1NC2=CC(=CC=C2C=1C(=NC1=CC=C(C=C1)N(C(CN1CCN(CC1)C)=O)C)C1=CC=CC=C1)C(=O)OC CPMDPSXJELVGJG-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000033829 multifocal fibrosclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937272P | 2014-02-07 | 2014-02-07 | |
| US61/937,272 | 2014-02-07 | ||
| US201462010004P | 2014-06-10 | 2014-06-10 | |
| US62/010,004 | 2014-06-10 | ||
| US201462037497P | 2014-08-14 | 2014-08-14 | |
| US62/037,497 | 2014-08-14 | ||
| PCT/US2015/014939 WO2015120350A2 (en) | 2014-02-07 | 2015-02-07 | Compositions and methods for treating fibrotic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106102775A true CN106102775A (zh) | 2016-11-09 |
Family
ID=52684645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580007480.7A Pending CN106102775A (zh) | 2014-02-07 | 2015-02-07 | 治疗纤维变性疾病的方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9993494B2 (enExample) |
| EP (1) | EP3102703A2 (enExample) |
| JP (1) | JP2017510552A (enExample) |
| CN (1) | CN106102775A (enExample) |
| AU (1) | AU2015213721B2 (enExample) |
| CA (1) | CA2938592A1 (enExample) |
| WO (1) | WO2015120350A2 (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106983738A (zh) * | 2017-04-13 | 2017-07-28 | 深圳市润佳通科技有限公司 | 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防皮肤疾病的药物中的应用 |
| CN107260730A (zh) * | 2017-05-31 | 2017-10-20 | 上海市东方医院 | 组蛋白去乙酰化酶hdac6的抑制剂在制备防治腹膜透析后腹膜纤维化的药物中的用途 |
| CN107326093A (zh) * | 2017-09-04 | 2017-11-07 | 东南大学 | 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用 |
| CN107916254A (zh) * | 2017-11-29 | 2018-04-17 | 武汉大学 | Homer1单克隆抗体及其应用 |
| CN108192984A (zh) * | 2018-02-13 | 2018-06-22 | 浙江大学 | 与湖羊肉质性状相关的分子标记及特异性引物对和应用 |
| CN111228464A (zh) * | 2020-02-28 | 2020-06-05 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 广谱抗冠状病毒的多肽及其用途 |
| CN113679841A (zh) * | 2020-05-19 | 2021-11-23 | 上海市同济医院 | 一种磷脂酶d1(pld1)基因及其抑制剂在肝纤维化防治中的应用 |
| CN119925378A (zh) * | 2023-11-03 | 2025-05-06 | 成都嘉葆药银医药科技有限公司 | 吡咯并三嗪类化合物在制备预防和/或治疗纤维化或其相关疾病的药物中的应用 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| US11026945B2 (en) * | 2016-04-29 | 2021-06-08 | The Trustees Of The University Of Pennsylvania | Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation |
| US10894960B2 (en) | 2016-08-30 | 2021-01-19 | Children's Hospital Medical Center | Compositions and methods for nucleic acid transfer |
| WO2018055578A1 (en) | 2016-09-22 | 2018-03-29 | The University Of Hong Kong | Preventive and therapeutic approach for aberrant cell differentiation and isr-associated diseases |
| WO2018149978A1 (en) * | 2017-02-16 | 2018-08-23 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | ALTERNATIVE ACTIVATION OF MACROPHAGES (M2 CELLS) THROUGH THE POLYAMINE-eIF5a-HYPUSINE AXIS |
| US12411144B2 (en) | 2017-03-22 | 2025-09-09 | Children's Hospital Medical Center | Compositions and methods for treatment of lung function |
| KR102641269B1 (ko) * | 2017-05-24 | 2024-02-26 | 이펙터 테라퓨틱스, 인크. | 개선된 항종양 면역 반응을 위한 조성물 및 방법 |
| PL3658141T3 (pl) | 2017-07-24 | 2023-06-12 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47 |
| EA202090393A1 (ru) | 2017-07-28 | 2020-05-20 | Кёрин Фармасьютикал Ко., Лтд. | Терапевтическое средство от фиброза |
| WO2019180664A1 (en) * | 2018-03-21 | 2019-09-26 | The University Of Hong Kong | Method for preventing or modulating fibrosis and fibrotic response associated with the integrated stress response |
| AU2020299362A1 (en) | 2019-07-02 | 2022-02-24 | Effector Therapeutics, Inc. | EiF4e-inhibiting 4-OXO-3,4-dihydropyrido(3,4-d)pyrimidine compounds |
| KR102100163B1 (ko) * | 2019-09-24 | 2020-04-13 | 테고사이언스 (주) | 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물 |
| US20230181582A1 (en) | 2020-05-22 | 2023-06-15 | Qx Therapeutics Inc. | Compositions and methods for treating lung injuries associated with viral infections |
| WO2021243319A1 (en) * | 2020-05-29 | 2021-12-02 | Novomedix, Llc | Biarylsulfonamides and pharmaceutical compositions thereof, and their use for treating fibrotic lung disease |
| US20230374591A1 (en) * | 2020-10-08 | 2023-11-23 | The Trustees Of Dartmouth College | Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions |
| US20240066021A1 (en) * | 2021-01-15 | 2024-02-29 | Children's Hospital Medical Center | Methods for optimizing cftr-modulator therapy |
| GB202109534D0 (en) * | 2021-07-01 | 2021-08-18 | Anglia Ruskin Univ Higher Education Corporation | Treatment of scarring |
| EP4374868A4 (en) * | 2021-07-22 | 2025-08-06 | Shanghai Synvida Biotechnology Co Ltd | PHARMACEUTICAL COMPOSITION OR MEDICINE KIT FOR RELIEVING OR TREATING FIBROTIC DISEASES, AND ITS USE |
| CN118804976A (zh) * | 2021-12-17 | 2024-10-18 | 雷杰纳荣制药公司 | 用整联蛋白亚基α1(ITGA1)抑制剂治疗肺部疾患 |
| CN115558712A (zh) * | 2022-09-22 | 2023-01-03 | 华中科技大学同济医学院附属协和医院 | Fam177a1的新用途 |
| CN117589999A (zh) * | 2023-11-17 | 2024-02-23 | 深圳市人民医院 | Pfkp作为慢性肾脏疾病治疗靶点的应用及其抑制剂 |
| CN120789266A (zh) * | 2025-09-10 | 2025-10-17 | 山东第一医科大学第一附属医院(山东省千佛山医院) | Eif3a抑制剂在制备治疗肝纤维化药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090220488A1 (en) * | 2005-08-31 | 2009-09-03 | Humphrey Gardner | Evaluating and treating scleroderma |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046219A (en) | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| EP1693059A1 (en) | 2005-02-22 | 2006-08-23 | Deutsches Krebsforschungszentrum | Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases |
| JP4512828B2 (ja) | 2005-04-12 | 2010-07-28 | 国立大学法人 千葉大学 | 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット |
| GB0617117D0 (en) | 2006-08-31 | 2006-10-11 | Renovo Ltd | Method of diagnosis |
| US20090004668A1 (en) * | 2007-06-22 | 2009-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Pre-miRNA loop-modulated target regulation |
| US7550300B1 (en) | 2007-11-29 | 2009-06-23 | Capgen Sciences, Inc. | Prediction of bare metal stent restenosis |
| CA2742298C (en) | 2008-11-03 | 2019-09-10 | The Regents Of The University Of California | Methods for detecting modification resistant nucleic acids |
| AU2009321723A1 (en) | 2008-12-05 | 2010-06-10 | Intermed Discovery Gmbh | Inhibitors of HIF-1 protein accumulation |
| US20100152531A1 (en) * | 2008-12-11 | 2010-06-17 | Paracor Medical, Inc. | Implantable medical device for drug delivery and method of use |
| WO2010080248A2 (en) | 2008-12-18 | 2010-07-15 | The Board Of Regents Of The University Of Texas System | Peptides that bind eukaryotic translation initiation factor 4e |
| CN102640001A (zh) | 2009-11-05 | 2012-08-15 | 诺瓦提斯公司 | 预测纤维化进展的生物标记物 |
| FR2954943B1 (fr) * | 2010-01-07 | 2013-03-01 | Sanofi Aventis | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
| US8877188B2 (en) | 2010-05-04 | 2014-11-04 | The Brigham And Women's Hospital, Inc. | Detection and treatment of non-dermal fibrosis |
| WO2011140334A2 (en) | 2010-05-06 | 2011-11-10 | Trustees Of Boston University | Compounds, methods of making or identifying compounds, and uses thereof |
| EP2576532B1 (en) | 2010-06-07 | 2018-07-18 | Novomedix, LLC | Furanyl compounds and the use thereof |
| JP2013533258A (ja) | 2010-06-28 | 2013-08-22 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 細胞増殖を阻害するための化合物 |
| US9156781B2 (en) | 2012-11-30 | 2015-10-13 | Novomedix, Llc | Substituted biaryl sulfonamides and the use thereof |
| US20140243356A1 (en) | 2013-02-07 | 2014-08-28 | The Regents Of The University Of California | Use of translational profiling to identify target molecules for therapeutic treatment |
| WO2014124412A2 (en) | 2013-02-11 | 2014-08-14 | President And Fellows Of Harvard College | Methods and compounds for the inhibition of cellular proliferation |
-
2015
- 2015-02-07 WO PCT/US2015/014939 patent/WO2015120350A2/en not_active Ceased
- 2015-02-07 AU AU2015213721A patent/AU2015213721B2/en not_active Ceased
- 2015-02-07 EP EP15710297.1A patent/EP3102703A2/en not_active Withdrawn
- 2015-02-07 CN CN201580007480.7A patent/CN106102775A/zh active Pending
- 2015-02-07 US US14/616,690 patent/US9993494B2/en active Active
- 2015-02-07 JP JP2016550760A patent/JP2017510552A/ja active Pending
- 2015-02-07 CA CA2938592A patent/CA2938592A1/en not_active Abandoned
-
2018
- 2018-05-07 US US15/973,281 patent/US10576098B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090220488A1 (en) * | 2005-08-31 | 2009-09-03 | Humphrey Gardner | Evaluating and treating scleroderma |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106983738A (zh) * | 2017-04-13 | 2017-07-28 | 深圳市润佳通科技有限公司 | 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防皮肤疾病的药物中的应用 |
| CN107260730A (zh) * | 2017-05-31 | 2017-10-20 | 上海市东方医院 | 组蛋白去乙酰化酶hdac6的抑制剂在制备防治腹膜透析后腹膜纤维化的药物中的用途 |
| CN107260730B (zh) * | 2017-05-31 | 2019-10-22 | 上海市东方医院 | 组蛋白去乙酰化酶hdac6的抑制剂在制备防治腹膜透析后腹膜纤维化的药物中的用途 |
| CN107326093A (zh) * | 2017-09-04 | 2017-11-07 | 东南大学 | 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用 |
| CN107326093B (zh) * | 2017-09-04 | 2020-01-21 | 东南大学 | 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用 |
| CN107916254A (zh) * | 2017-11-29 | 2018-04-17 | 武汉大学 | Homer1单克隆抗体及其应用 |
| CN107916254B (zh) * | 2017-11-29 | 2020-05-12 | 武汉大学 | Homer1单克隆抗体及其应用 |
| CN108192984A (zh) * | 2018-02-13 | 2018-06-22 | 浙江大学 | 与湖羊肉质性状相关的分子标记及特异性引物对和应用 |
| CN111228464A (zh) * | 2020-02-28 | 2020-06-05 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 广谱抗冠状病毒的多肽及其用途 |
| CN113679841A (zh) * | 2020-05-19 | 2021-11-23 | 上海市同济医院 | 一种磷脂酶d1(pld1)基因及其抑制剂在肝纤维化防治中的应用 |
| CN119925378A (zh) * | 2023-11-03 | 2025-05-06 | 成都嘉葆药银医药科技有限公司 | 吡咯并三嗪类化合物在制备预防和/或治疗纤维化或其相关疾病的药物中的应用 |
| WO2025092340A1 (zh) * | 2023-11-03 | 2025-05-08 | 成都嘉葆药银医药科技有限公司 | 吡咯并三嗪类化合物在制备预防和/或治疗纤维化或其相关疾病的药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150224132A1 (en) | 2015-08-13 |
| WO2015120350A2 (en) | 2015-08-13 |
| JP2017510552A (ja) | 2017-04-13 |
| AU2015213721A1 (en) | 2016-07-28 |
| CA2938592A1 (en) | 2015-08-13 |
| WO2015120350A3 (en) | 2015-10-01 |
| AU2015213721B2 (en) | 2021-05-20 |
| US9993494B2 (en) | 2018-06-12 |
| US10576098B2 (en) | 2020-03-03 |
| US20190038657A1 (en) | 2019-02-07 |
| EP3102703A2 (en) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106102775A (zh) | 治疗纤维变性疾病的方法 | |
| Zhao et al. | Anti‐aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application | |
| Gulati et al. | The aging lung and idiopathic pulmonary fibrosis | |
| Zank et al. | Idiopathic pulmonary fibrosis: aging, mitochondrial dysfunction, and cellular bioenergetics | |
| Wells et al. | Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma | |
| Zhang et al. | WNT signaling underlies the pathogenesis of neuropathic pain in rodents | |
| Lu et al. | Targeting WWP1 ameliorates cardiac ischemic injury by suppressing KLF15-ubiquitination mediated myocardial inflammation | |
| Kaplan et al. | Extracellular functions of 14-3-3 adaptor proteins | |
| Domaniku-Waraich et al. | Oncostatin M signaling drives cancer-associated skeletal muscle wasting | |
| Cao et al. | WNT10A induces apoptosis of senescent synovial resident stem cells through Wnt/calcium pathway-mediated HDAC5 phosphorylation in OA joints | |
| Maser et al. | The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma | |
| Zhou et al. | Primary cilia: A cellular regulator of articular cartilage degeneration | |
| Wei et al. | Restoration of H3k27me3 modification epigenetically silences Cry1 expression and sensitizes leptin signaling to reduce obesity‐related properties | |
| Alenchery et al. | PAI‐1 mediates TGF‐β1‐induced myofibroblast activation in tenocytes via mTOR signaling | |
| Ma et al. | Phillyrin: a potential therapeutic agent for osteoarthritis via modulation of NF-κB and Nrf2 signaling pathways | |
| Bei et al. | Heterotopic ossification: Current developments and emerging potential therapies | |
| Zhu et al. | TNKS1BP1 mediates AECII senescence and radiation induced lung injury through suppressing EEF2 degradation | |
| US20210353681A1 (en) | Use of tnks inhibitors for regeneration of cartilage | |
| Tsoyi et al. | Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development? | |
| Zeng et al. | Nicotinamide phosphoribosyltransferase inhibitor ameliorates mouse aging-induced cognitive impairment | |
| Yu et al. | Inhibitor of DNA-binding 1 promotes endothelial progenitor cell proliferation and migration by suppressing E2-2 through the helix-loop-helix domain | |
| Xi et al. | Association of alpha-soluble NSF attachment protein with epileptic seizure | |
| Alghanem et al. | Effect of insulin and pioglitazone on protein phosphatase 2a interaction partners in primary human skeletal muscle cells derived from obese insulin-resistant participants | |
| Hahm et al. | Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation | |
| Zhou et al. | A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161109 |
|
| WD01 | Invention patent application deemed withdrawn after publication |